Growth drivers like booming geriatric population, escalating healthcare expenditure, rising cases of chronic disorders, and increasing pipeline of age-related macular degeneration (AMD) therapeutics will boost the age-related macular degeneration market growth, at a CAGR of 7.6%, during 2016–2022. At this rate, revenue of the market is expected to rise from $5.3 billion in 2015 to $8.9 billion by 2022. AMD is a retinal disorder that leads to visual impairment or blindness among elderly people. It is primarily the degeneration or deterioration of the macula leading to vision loss.

Receive Sample Copy of this Report:https://www.psmarketresearch.com/market-analysis/age-related-macula...

Moreover, increasing government expenditure for the development of healthcare infrastructure to curtail financial burden on patients is one of the key factors driving the age-related macular degeneration market. Globally, healthcare burden has increased significantly and becomes a notable reason for concerns among patients and healthcare providers. Some of the key reasons behind the soaring cost include escalating fees of physicians and rising cost of advanced treatment methods. The treatment of AMD requires expensive treatment methods that are being made available at a reduced cost, due to the support from governments.

Make an Enquiry before Purchase:https://www.psmarketresearch.com/send-enquiry?enquiry-url=age-relat...

The categories under the drug segment of the age-related macular degeneration market include Lucentis, Eylea, Avastin, Visudyne, and others (including Visudyne and Macugen). Among these, the Lucentis category is expected to hold the largest market share in the forecast period. Moreover, the demand for Eylea is also expected to rise in the coming years, due to the increasing prevalence of wet AMD and higher efficiency and lower cost of this drug in comparison to other medications.